Sanofi says filed investor presentation on proposed acquisition of Medivation with the U.S. Securities and Exchange Commission

* Sanofi says its proposal is not subject to any financing condition,

* Sanofi says it is confident in its ability to receive all regulatory approvals

* Sanofi says its is willing to enter into customary confidentiality agreement which would include a standstill clause to give time for Medivation to conduct a sale process

* Sanofi says the record date to determine Medivation shareholders entitled to give their written consent has been established as June 1 and expects the initial Hart-Scott-Rodino (HSR) waiting period to expire on June 13.

* Sanofi says it anticipates filing definitive consent solicitation materials in mid-June

* Sanofi says it has signed a consent on June 3 for the shares it owns in Medivation and therefore expects that the 60-day consent solicitation period will conclude no later than August 1 Further company coverage: (Paris Newsroom)